Irinotecan (CPT-11) metabolism and disposition in cancer patients

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2747-2754

  Sparreboom, Alex ^a   De Jonge, Maja J A ^a   De Bruijn, Peter ^a   Brouwer, Eric ^a   Nooter, Kees ^a   Loos, Walter J ^a   Van Alphen, Robbert J ^a   Mathijssen, Ron H J ^a   Stoter, Gerrit ^a   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; IRINOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 0031785256     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Creemers, G. J., Lund, B., and Verweij, J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20: 73-96, 1994.
2. Gerrits, C. J. H., de Jonge, M. J. A., Schellens, J. H. M., Stoter, G., and Verweij, J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer, 76: 952-962, 1997.
3. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
4. Tsuji, T., Kaneda, N., Kado, N., Yokokura, T., Yoshimoto T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobio-dyn., 14: 341-349, 1991.
5. Rivory, L. P., Bowles, M. R., Robert J., and Pond, S. M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol., 52: 1103-1111, 1996.
6. Zamboni, W. C., Houghton, P. J., Thompson, J., Cheshire, P. J., Hanna, S. K., Richmond, L. B., Lou, X., and Stewart, C. F. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin. Cancer Res., 4: 455-462, 1998.
7. Danks, M. K., Morton, C. L., Pawlik, C. A., and Potter, P. M. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res., 58: 20-22, 1998.
8. Atsumi, R., Okazaki O., and Hakusui, H. Metabolism of irinotecan to SN-38 in a tumor-isolated tumor model. Biol. Pharm. Bull., 18: 1024-1026, 1995.
9. Rivory, L. P., and Robert, J. Identification and kinetics of a β-glu-curonide metabolite of SN-38 in human plasma after administration of the camptothecine derivative irinotecan. Cancer Chemother. Pharmacol., 36: 176-179, 1995.
10. Haaz, M-C., Rivory, L. P., Jantet S., Ratanasavanh, D., and Robert, J. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol. Toxicol., 80: 91-95, 1997.
11. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, M. D., Tephly, T. R., Coffman, B. L., and Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11 ). Role of uridine glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest., 101: 847-854, 1998.
12. Lokiec, F., Monegier du Sorbier, B., and Sanderink, G. J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 2: 1943-1949, 1996.
13. Haaz, M-C., Rivory, L. P., Riché, C., Vernillet, L., and Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res., 58: 468-472, 1998.
14. Rivory, L. P., Riou, J. F., Haaz, M-C., Sable, S., Vuilhorgne, M., Commerçon, A., Pond S. M., and Robert, J. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res., 56: 3689-3694, 1996.
15. Dodds, H. M., Haaz, M-C., Riou, J. F., Robert, J., and Rivory, L. P. Identification of a new metabolite of CPT-11 (irinotecan). Pharmacoxlogical properties and activation to SN-38. J. Pharmacol. Exp. Ther., 281: 578-583, 1998.
16. De Bruijn, P., Verweij, J., Loos, W. J., Nooter, K., Stoter G., and Sparreboom, A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr., 698: 277-285, 1997.
17. Sparreboom, A., De Bruijn, P., De Jonge, M. J. A., Loos, W. J., Stoter, G., Verweij, J., and Nooter, K. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J. Chromatogr., 712: 225-235, 1998.
18. Verweij, J., de Jonge, M. J. A., Sparreboom, A., Planting, A. S. T., Van der Burg, M. E. L., De Boer-Dennert, M. M., Ter Steeg, J., Jacques C., and Stoter, G. Phase I and pharmacokinetic study of irinotecan (CPT-11) and cisplatin in patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 17: 188a, 1998.
19. Bourzat, J. D., Vuilhorgne, M., Rivory L. P., and Robert, J. Semisynthesis of RPR121056A, a major metabolite of irinotecan (CPT-11). Tetrahedron Lett., 37: 6327-6330, 1997.
20. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S., and Boyd, M. R. New colorimetric cytoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
21. Ma, J., Maliepaard, M., Nooter, K., Boersma, A. W. M., Verweij, J., Stoter, G., and Schellens, J. H. M. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of 8 solid tumour cell lines in vitro. Cancer Chemother. Pharmacol., 41: 307-316, 1998.
22. Rivory, L. P., Haaz, M-C., Canal, P., Lokiec, F., Armand, J-P., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res., 3: 1261-1266, 1997.
23. Takimoto, C. H., and Arbuck, S. G. The camptothecins. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 463-484. Philadelphia: Lippincott-Raven Publishers, 1996.
24. Lokiec, F., Canal, P., Gay, C., Chatelut, E., Armand, J-P., Roché, H., Bugat, R., Gonçalvès E., and Mathieu-Boué, A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol., 36: 79-82, 1995.
25. Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., and Wienkers, L. C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos., 25: 1157-1164, 1997.
26. De Jonge, M. J. A., Sparreboom, A., and Verweij, J. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treat. Rev., 24: 205-220, 1998.
27. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T-L., Rock, M. K., and Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-piperidino]-carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
28. Rothenburg, M. L., Kuhn, J. G., Burris, H. W., Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M. K., and Von Hoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
29. Burke, T. G., Zoorob, G., Slatter J. G., and Schaaf, L. F. In vitro protein binding of CPT-11 metabolites SN-38, SN-38 glucuronide (SN-38G), and APC and possible displacement by commonly used comedications. Proc. Am. Soc. Clin. Oncol., 17: 195a, 1998.
30. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Yokes E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
31. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., De Forni, M., Extra, J-M., Mahjoubi, M., Hérait, P., Armand, J-P., Bugat, R., Clavel, M., and Marty, M. E. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase 1 trials. Ann. Oncol., 6: 141-151, 1995.
32. Chabot, G. G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet., 33: 245-259, 1997.
33. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., and Ratain, M. J. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol., 15: 1502-1510, 1997.
34. Van Asperen, J., Van Teilingen, O., Tijssen, F., Schinkel, A. H., and Beijnen, J. H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer, in press, 1998.
35. Takahashi, T., Fujiwara, Y., Sumiyoshi, H., Isobe, T., Yamaoka, N., and Yamakido, M. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother. Pharmacol., 40: 449-452, 1997.
36. Abigerges, D., Chabot, G. G., Armand, J-P., Hérait, P., Gouyette, A., and Gandia, D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
37. Kaneda, N., and Yokokura, T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res., 50: 1721-1725, 1990.
38. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi T., and Kamataki, T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res., 56: 3752-3757, 1996.
39. Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F., and Mathieu-Boue, A. Pharmacokinetics and pharmacodynamics of irinotecan during a Phase II clinical trial in colorectal cancer. J. Clin. Oncol., 14: 2688-2695, 1996.
40. Takasuna, K., Kasai, Y., Kitano, Y., Mori, K., Kobayashi, R., Hagiwara, T., Kakihata, H., Hirohashi, M., Nomura, M., Nagai, E., and Kamataki, T. Protective effects of kampo medicines and baicalin against intestinal toxicity of the new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11). Jpn. J. Cancer Res., 86: 978-984, 1995.